Table 3

DMARD and glucocorticoid use by patient characteristics among MCBS respondents with rheumatoid arthritis between 2001 and 2006, weighted to the US Medicare population

Total weighted number

(in thousands)

Any DMARD

Non-biologic DMARD

Biologic DMARD

Oral Glucocorticoid Use


N (%)*


Age, years

65 to 74

2,965

1,089 (37%)

1,021 (35%)

169 (6%)

1,010 (34%)

75 to 84

1,338

328 (25%)

323 (24%)

31 (2%)

376 (28%)

85+

353

15 (4%)

15 (4%)

0

80 (23%)

Gender

Female

3,440

1,071 (31%)

1,014 (30%)

173 (5%)

1,104 (32%)

Male

1,216

361 (30%)

346 (29%)

28 (2%)

361 (30%)

Race/ethnicity

Non-Hispanic, white

2,996

1,170 (33%)

1,145 (32%)

130 (4%)

1,186 (33%)

Non-Hispanic, black

413

119 (25%)

111 (23%)

11 (2%)

141 (29%)

Hispanic

364

90 (20%)

52 (12%)

60 (13%)

117 (26%)

Non-Hispanic, other

133

52 (33%)

52 (33%)

0

22 (14%)

Income (US dollars)

>50,000

260

126 (49%)

126 (49%)

30 (12%)

98 (38%)

>30,000 to 50.000

1,003

376 (38%)

353 (35%)

74 (7%)

353 (35%)

>20,000 to 30,000

992

309 (31%)

278 (28%)

65 (7%)

373 (38%)

>15,000 to 20,000

639

188 (30%)

175 (27%)

19 (3%)

175 (27%)

≤ 15,000

1,582

361 (23%)

358 (23%)

7 (0.5%)

392 (25%)


Total number = 4,656,213. *Percentage of the row total. DMARD, disease modifying anti-rheumatic drug use; MCBS, Medicare Current Beneficiary Survey.

Solomon et al. Arthritis Research & Therapy 2013 15:R43   doi:10.1186/ar4201

Open Data